SCOUR-X ORAL ANTI-DIARRHOEAL SUSPENSION Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

scour-x oral anti-diarrhoeal suspension

ausrichter pty ltd - neomycin sulfate; hyoscine as hyoscine methobromide; pectin; kaolin light; sulfadimidine; sulfadiazine; vitamin b2 = riboflavin; vitamin b1 hydrochloride = thiamine hydrochloride - oral solution/suspension - neomycin sulfate antibiotic active 54.0 mg/30ml; hyoscine as hyoscine methobromide alkaloid active 0.91 mg/30ml; pectin carbohydrate active 213.0 mg/30ml; kaolin light clay active 3.1 g/30ml; sulfadimidine sulfanyl active 852.0 mg/30ml; sulfadiazine sulfanyl active 1278.0 mg/30ml; vitamin b2 = riboflavin vitamin-b2 active 6.6 mg/30ml; vitamin b1 hydrochloride = thiamine hydrochloride vitamin-b1 active 4.5 mg/30ml - alimentary system - calf | cat | dog | horse | beef calf | bitch | bovine | calf - poddy | calf - preweaning | calf - sucker | castrate | cat - quee - bacterial enteritis | post-weaning bacterial enterit

Sulfadiazine 500mg Tablets BP Malta - English - Medicines Authority

sulfadiazine 500mg tablets bp

wockhardt uk limited ash road north, wrexham, ll13 9uf, united kingdom - sulfadiazine - tablet - sulfadiazine 500 mg - antibacterials for systemic use

SULFADIAZINE tablet United States - English - NLM (National Library of Medicine)

sulfadiazine tablet

eon labs, inc. - sulfadiazine (unii: 0n7609k889) (sulfadiazine - unii:0n7609k889) - sulfadiazine tablets, usp are indicated in the following conditions: chancroid trachoma inclusion conjunctivitis nocardiosis urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, staphylococcus aureus , proteus mirabilis and p. vulgaris . sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. malaria due to chloroquine-resistant strains of plasmodium falciparum , when used as adjunctive therapy. prophylaxis of meningococcal meningitis when sulfonamide-sensitive group a strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides

SULFADIAZINE tablet United States - English - NLM (National Library of Medicine)

sulfadiazine tablet

epic pharma, llc - sulfadiazine (unii: 0n7609k889) (sulfadiazine - unii:0n7609k889) - sulfadiazine tablets, usp are indicated in the following conditions: chancroid trachoma inclusion conjunctivitis nocardiosis urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: escherichia coli, klebsiella species, enterobacter species, staphylococcus aureus, proteus mirabilis and p. vulgaris . sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. malaria due to chloroquine-resistant strains of plasmodium falciparum , when used as adjunctive therapy. prophylaxis of meningococcal meningitis when sulfonamide-sensitive group a strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group b or c infections are prevalent is not proved and may be harmful in closed population groups). meningococcal meningitis, when the organism has been demonstrated to be susceptible. acute otitis media due to haemophilus influenzae, when used concomitantly with adequate doses of penicilin. prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. h. influenzae meningitis, as adjunctive therapy with parental streptomycin. important notes in vitro sulfonamide susceptibility tests are not always reliable. the test must be carefully coordinated with bacteriologic and clinical response. when the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. wide variation in blood levels may result with identical doses. blood levels should be measured in patients receiving sulfonamides for serious infections. free sulfonamide blood levels of 5 mg to 15 mg per 100 ml may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 ml may be considered optimal for serious infections. twenty mg per 100 ml should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. sulfadiazine is contraindicated in the following circumstances: hypersensitivity to sulfonamides. in infants less than 2 months of age (except as adjunctive therapy with pyrimethamine in the treatment of congenital toxoplasmosis). in pregnancy at term and during the nursing period, because sulfonamides cross the placenta and are excreted in breast milk and may cause kernicterus.